Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Dose, Open-label, Randomized Two-period Crossover Study in Healthy Young Subjects to Assess the Absolute Bioavailability of Ipragliflozin

NCT01611428 is registered in ClinicalTrials.gov with Astellas Pharma Europe B.V. as lead sponsor.

NCT NCT01611428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01611428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Dose, Open-label, Randomized Two-period Crossover Study in Healthy Young Subjects to Assess the Absolute Bioavailability of Ipragliflozin
Lead sponsor
Astellas Pharma Europe B.V.
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2011
Completion date
July 31, 2011
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bioavailability of ipragliflozin, healthy subjects